1 unknown. 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 1 | Unknown 1 |
Follow Kathelijn Fischer: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetic-guided Dosing of Emicizumab Emicizumab - PK-guided dose reduction, Emicizumab - Dosis continuation group, Emicizumab - Dose adjustment group - Hemophilia A With Inhibitor, Hemophilia A Without Inhibitor | Phase 4 | Unknown | Kathelijn Fischer | 95 | 2022-09-08 | 2024-03-20 |
Hemophilia A (1) · Hemorrhage (1)
emicizumab (1)
Netherlands (1)